Nikesh Shah, MD

198 posts

Nikesh Shah, MD

Nikesh Shah, MD

@TheOncDoc

Hematologist/Oncologist @TGHCares Cancer Institute. Trained @MoffittNews, @EmoryDeptofMed, @umiamimedicine. Interest in lymphoma. All tweets my own.

Tampa, FL 가입일 Eylül 2019
170 팔로잉327 팔로워
Nikesh Shah, MD 리트윗함
Journal of Clinical Oncology
Journal of Clinical Oncology@JCO_ASCO·
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-cell Lymphoma: Primary Results of the Phase 3 SUNMO Trial. Co-authored by @Lymphoma_Doc Read the full article brnw.ch/21wWoAi #lymsm
English
0
5
26
2.5K
Nikesh Shah, MD
Nikesh Shah, MD@TheOncDoc·
including an oral presentation on 1L epco+polaRCHP by Alan Kerr and a poster on germline sequencing in AML by Anna (Ania) Krzeczowska, DNP, AOCNP, AGACNP-BC On to Lugano!
Nikesh Shah, MD tweet media
Polski
0
0
3
75
Nikesh Shah, MD
Nikesh Shah, MD@TheOncDoc·
Had a great time in Milano at EHA! Presented data from our novel program delivering inpatient-level care at home to patients with Heme malignancies. Proud to have multiple presentations from Tampa General Hospital Cancer Institute
English
2
0
3
132
Nikesh Shah, MD
Nikesh Shah, MD@TheOncDoc·
Had a blast discussing CAR-T and bispecifics in lymphoma with Alan Kerr! Excited to bring these game changing therapies to our patients @TGHCares
Tampa General Hospital@TGHCares

An episode of MD Cast by Tampa General Hospital podcast is here! Titled "Immunotherapies in Lymphoma: CAR-T and Bispecific Antibodies," Dr. Nikesh Shah & Dr. D. Alan Kerr II join us from the TGH Cancer Institute to share expert insights. CME/CEU available: tgh.org/MDCast

English
0
0
10
603
Nikesh Shah, MD 리트윗함
calliecoombs
calliecoombs@calliecoombsmd·
Interesting study on burnout in hem/onc - working with APPs (not surprising!) and being young are protective but being female 💆🏻‍♀️ and RVU-only based compensation increase odds for burnout. ashpublications.org/bloodadvances/…
English
2
25
64
27.3K
Nikesh Shah, MD
Nikesh Shah, MD@TheOncDoc·
Glofitamab just approved in r/r DLBCL after 2 lines. Also requires hospitalization for full dose like Epco. Biggest difference is finite duration. fda.gov/drugs/drug-app…
English
1
0
2
392
Yumeng (Julia) Zhang
Yumeng (Julia) Zhang@yumengzhang2009·
Thrilled to share that I've been honored with the #ASCO YIA award! A heartfelt thanks to all my mentors who have guided me tirelessly.I remain dedicated to my clinical focus on lymphoma, and to every patient who inspires me daily. #LymphomaResearch #Gratitude @MoffittNews
Conquer Cancer, the ASCO Foundation@ConquerCancerFd

Introducing the 2023 #ConquerCancer Grant & Award recipients! $11M in awards to over 400 recipients in 33 countries. These grants support a diverse set of #onc professionals to help accelerate #CancerReserch breakthroughs. bit.ly/3ICeUIK #OncAlert #ASCO23 @ASCO

English
7
3
19
3.8K
Nikesh Shah, MD
Nikesh Shah, MD@TheOncDoc·
Incredibly humbling and inspiring to present our work on TP53 altered mantle cell lymphoma at the @lymphoma MCL Consortium to giants in the field who literally defined the disease and how we manage it to this day. Fantastic conference chaired by Dr. Eduardo Sotomayor #lymsm
Nikesh Shah, MD tweet mediaNikesh Shah, MD tweet media
English
2
2
29
2.2K
Nikesh Shah, MD
Nikesh Shah, MD@TheOncDoc·
Pola-R-CHP approved for DLBCL or HGBCL with IPI 2 or higher based on POLARIX data. Interesting since subgroup analysis showed less benefit for IPI 2, GCB, and double hit (of course not powered for this). Will you use universally for this population? Longer fu is crucial #lymsm
Nikesh Shah, MD tweet media
English
0
0
2
392
Nikesh Shah, MD 리트윗함
Mark Lewis, MD, FASCO
Mark Lewis, MD, FASCO@marklewismd·
An absolutely maddening, but telling excerpt from the @propublica report on UnitedHealthcare denying a patient's much-needed ulcerative colitis treatment 👇 Often, the arbiters of what is "clinically appropriate" don't have subspecialty expertise or up-to-date practice patterns!
Mark Lewis, MD, FASCO tweet media
English
5
13
86
12.2K
Nikesh Shah, MD
Nikesh Shah, MD@TheOncDoc·
MCL TRIANGLE Study- well-deserved Plenary at #ASH22! Young pts w new MCL- RCHOP/DHAP+auto in CR1 is not superior to RCHOP/DHAP+ibrutinib ->I maint.
Nikesh Shah, MD tweet media
English
2
0
15
0
Nikesh Shah, MD
Nikesh Shah, MD@TheOncDoc·
Interestingly, receipt of rituximab maintenance did not impact outcomes, though this wasn't randomized. Will be interesting to compare w/ ECOG-ACRIN 4151 results. #lymsm
English
0
0
3
0

탐색

@JCO_ASCO @elizabeth_budde @Lymphoma_Doc @TGHCares @yumengzhang2009 @MoffittNews @lymphoma @propublica